Fulltext

Staggering the dose of sugammadex lowers risks for severe emergence cough: a randomized control trial

P S L 1 , Miskan MM 2 , Y Z C 3 , Zaki RA 4

Affiliations 

  • 1 Department of Anesthesiology and Intensive Care, University Malaya, Lembah Pantai, 50603, Kuala Lumpur, Malaysia. lohps@ummc.edu.my
  • 2 Kuching Hospital, Sarawak, Malaysia
  • 3 Department of Anesthesiology and Intensive Care, University Malaya, Lembah Pantai, 50603, Kuala Lumpur, Malaysia
  • 4 Julius Centre University of Malaya, Department of Social & Preventive Medicine, Faculty of Medicine, University Malaya, Kuala Lumpur, Malaysia
BMC Anesthesiol, 2017 Oct 11;17(1):137.
PMID: 29020936 DOI: 10.1186/s12871-017-0430-3

Abstract

BACKGROUND: Cough on emergence has been reported as a common adverse reaction with sugammadex reversal. We investigated if staggering the dose of sugammadex will reduce emergence cough in a single-center, randomized, double-blinded study.

METHODS: A hundred and twenty ASA 1-3 adults were randomly reversed with 1 mg/kg sugammadex prior to extubation followed by another 1 mg/kg immediately after extubation (staggered group), single dose of 2 mg/kg sugammadex (single bolus group) or neostigmine 0.02 mg/kg with glycopyrrolate (neostigmine group).

RESULTS: We found 70% of patients (n = 28) reversed with single boluses of sugammadex had Grade 3 emergence cough compared to 12.5% (n = 5) in the staggered sugammadex group and 17.5% (n = 7) in the neostigmine group (p 

* Title and MeSH Headings from MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

MeSH terms
Similar publications